MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

VOLUNTARY ANNOUNCEMENT

NEW ENGLAND JOURNAL OF MEDICINE AND THE *EUROPEAN SOCIETY OF CARDIOLOGY* CONGRESS PUBLISHES EVIDENCE-BASED MEDICAL FINDINGS CONCURRENTLY VALIDATING THAT PATIENTS SUFFERING LOW-RISK MYOCARDIAL INFARCTION REQUIRE A MERE ONE-MONTH DUAL ANTIPLATELET THERAPY WHEN IMPLANTED WITH FIREHAWK® STENTS, WITH A DECREASE OF 54% IN BLEEDING COMPLICATIONS

This announcement is made by MicroPort Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce the *New England Journal of Medicine* (NEJM) has recently published the full text of the results of the TARGET-FIRST clinical trial conducted in Europe for the Firehawk® Drug Eluting Stent System (the "**Firehawk® Stent(s)**"), independently developed by the Group; the results were simultaneously presented during the "HOT LINE" session at the *European Society of Cardiology* Congress 2025 (ESC 2025) convened in Spain. Specifically, for patients suffering low-risk acute myocardial infarction (AMI) who undergo complete revascularization with Firehawk® Stents, the duration of dual antiplatelet therapy (DAPT) can be reduced from 12 months to 1 month. The therapy not only avoids increased ischaemic risks but also substantially reduces bleeding complications.

The *New England Journal of Medicine*, ranked the top among the four major leading medical journals in the world, is renowned for its high impact factor, rigorous peer review, and superb global academic influence, and its authority is generally accepted as the highest benchmark for evaluating scientific innovation and clinical achievements. Also, the *European Society of Cardiology* Congress is regarded as the global-leading academic gathering on cardiology. Such simultaneous exposure through "fast-track publication in a premier journal coupled with a dedicated session at a leading academic conference" is exceptionally rare, and can only be seen when it comes to the achievements of unprecedented research with the potential to rapidly transform global clinical practice and possess significant public health implications. The honour and privilege garnered by the TARGET-FIRST study fully reflects its academic status and the unique value of the Firehawk® Stents on clinical applications.

TARGET AC, a previous clinical trial of Firehawk® Stents in Europe, was published in *The Lancet*, the global-leading journal, for resolving the longstanding medical conundrum of late stent thrombosis, thereby garnering global attention to this Chinese-made product. As validated by two totally independent large-scale clinical studies conducted in Europe in terms of its clinical benefits, and given its potential of cost-effectiveness and advantage of humanity to a certain extent proved as well, Firehawk® Stent is expected to be one of rare medical solutions enabling the co-existence of "high quality, cost-effectiveness, and accessibility," with its possession of the key factors to substantially influence clinical practice and integrated treatment strategies in the cardiovascular discipline. The Group is always committed to developing innovative medical devices and technologies, and collaborating with world-class researchers to ensure that Chinese-made products make their presence on the global stage backed by objective data and validated by robust clinical evidence demonstrating safety and efficacy, and that our technologies enable more patients to benefit.

About the Firehawk® Stent

Firehawk® Stent is the third-generation coronary drug-eluting stent system independently developed by the Group, encompassing both of the feature of "low restenosis rate" of drug-eluting stents and the advantage of "extremely low late stent thrombosis rate" of bare-metal stents. This system employs the design of intermittent drug loading via single-sided grooves with the controlled-release of drug polymer. The drug/coating polymer rigorously encapsulated by the grooves will be released only upon reaching the area of vascular lesion, which achieves the "targeted, time-controlled, and quantitative" release of rapamycin. With a drug load of merely one-third that of conventional stents and a coating area merely constituting around 5% of the total metal surface, the Firehawk® Stent basically retains the structural morphology of a bare-metal stent, thus enabling itself to achieve rapid effects of endothelialization and healing comparable to bare-metal stents while maintaining its drug-eluting properties and fundamental functionality. The TARGET-FIRST study has further validated the systematic clinical benefits of the philosophy of such unique design of the Group, namely to maximize the approximation of bare-metal stents in terms of coating area and drug load.

To date, Firehawk® Stents have entered 67 countries and regions across Asia, Europe, the Americas, Africa, and Oceania. As encouraged by the clinical results of the TARGET-FIRST study, the Group will focus on its subsequent layout on commercializations and promotions for Firehawk® Stents in the North America regions.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 1 September 2025

As at the date of this announcement, the executive director of the Company is Dr. Zhaohua Chang; the non-executive directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*